1
|
Sarmikasoglou E, Chu L, Yue F, Faciola AP. Effects of ruminal lipopolysaccharide exposure on primary bovine ruminal epithelial cells. J Dairy Sci 2024; 107:1244-1262. [PMID: 37777002 DOI: 10.3168/jds.2023-23736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Accepted: 09/06/2023] [Indexed: 10/02/2023]
Abstract
The objective of this study was to investigate the immunopotential of ruminal lipopolysaccharides (LPS) on cultured primary bovine rumen epithelial cells (REC). Primary bovine REC were isolated from 6 yearling steers and grown in culture for 3 experiments. Experiment 1 aimed to determine the immunopotential of ruminal LPS, experiment 2 aimed to assess tolerance to chronic LPS exposure, and experiment 3 aimed to evaluate antagonistic interactions between ruminal and Escherichia coli LPS. In experiments 1 and 2, REC were exposed to nonpyrogenic water, 20 μg/mL E. coli LPS (EC20), 10 μg/mL ruminal LPS, 20 μg/mL ruminal LPS, and 40 μg/mL ruminal LPS, either continuously or intermittently. For the continuous exposure, REC underwent a 6 h exposure, whereas for the intermittent exposure, the procedure was: (1) a 12 h continuous exposure to treatments followed by LPS removal for 24 h and then another 12 h of exposure (RPT), and (2) a 12 h continuous exposure to treatments followed by LPS removal and a recovery period of 36 h (RCV). In experiment 3, REC were exposed to nonpyrogenic water, 1 μg/mL E. coli LPS, 1 μg/mL ruminal LPS to 1 μg/mL E. coli LPS, 10 μg/mL ruminal LPS to 1 μg/mL E. coli LPS, and 50 μg/mL ruminal LPS to 1 μg/mL E. coli LPS. Each experiment was done as a complete randomized block design with 6 REC donors. The REC-donor was used as blocking factor. Each treatment had 2 technical replicates, and treatment responses for all data were analyzed with the MIXED procedure of SAS. For all experiments, total RNA was extracted from REC and real-time quantitative PCR was performed to determine the relative expression of genes for toll-like receptors (TLR2 and TLR4), proinflammatory cytokines (TNF, IL1B, and IL6), chemokines (CXCL2 and CXCL8), growth factor-like cytokines (CSF2 and TGFB1), and a lipid mediator (PTGS2). In experiment 1, the targeted genes were upregulated by EC20, whereas all ruminal LPS treatments resulted in a lower transcript abundance. Regarding RPT, and RCV condition, in experiment 2, the expression of targeted genes was not affected or was at a lower abundance to EC20 when compared with ruminal LPS treatments. Lastly, in experiment 3, all targeted genes resulted in lower or similar transcript abundance on all ruminal LPS ratios. Overall, our results indicate that ruminal LPS have a limited capacity to activate the TLR4/NF-kB pathway and to induce the expression of inflammatory genes.
Collapse
Affiliation(s)
- E Sarmikasoglou
- Department of Animal Sciences, University of Florida, Gainesville, FL 32608
| | - L Chu
- Department of Animal Sciences, University of Florida, Gainesville, FL 32608
| | - F Yue
- Department of Animal Sciences, University of Florida, Gainesville, FL 32608
| | - A P Faciola
- Department of Animal Sciences, University of Florida, Gainesville, FL 32608.
| |
Collapse
|
2
|
Yu J, Jiang L, Zhao L, Wang X, Yang X, Yang D, Zhuo M, Chen H, Zhao YD, Zhou F, Li Q, Zhu Z, Chu L, Ma Z, Wang Q, Qu Y, Huang W, Zhang M, Gu T, Liu S, Yang Y, Yang J, Yu H, Yu R, Zhao J, Shi A. High Dose Hyperfractionated Thoracic Radiotherapy vs. Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicenter, Open-Label Randomized, Phase 3 Trial. Int J Radiat Oncol Biol Phys 2023; 117:S1. [PMID: 37784261 DOI: 10.1016/j.ijrobp.2023.06.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Limited stage small-cell lung cancer (LS-SCLC) is associated with poor prognosis. We aimed to assess the efficacy and safety of high-dose, hyperfractionated thoracic radiotherapy of 54 Gy in 30 fractions compared with standard dose (45 Gy in 30 fractions) as a first-line treatment for LS-SCLC. MATERIALS/METHODS The study was an open-label, randomized, phase 3 trial, done at 16 public hospitals in China. Key inclusion criteria were patients aged 18-70 years, with previously histologically or cytologically confirmed LS-SCLC, previously untreated or received 1-2 courses of intravenous cisplatin (75 mg/m²of body-surface area, on day 1 or divided into two days of each cycle) or carboplatin (area under the curve of 5 mg/mL per min, day 1 of each cycle)and intravenous etoposide (100 mg/m²of body-surface area, on days 1-3 of each cycle), and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.Eligible patients were randomly assigned (1:1) to receive volumetric-modulated arc radiotherapy (VMAT) of 45 Gy in 30 fractions or the simultaneous integrated boost VMAT (SIB-VMAT) of 54 Gy in 30 fractions to the primary lung tumor and lymph node metastases starting 0-42 days after the first chemotherapy course. Both groups of patients received thoracic radiotherapy twice per day and 10 fractions per week. Prophylactic cranial radiation (PCI, 25 Gy in 10 fractions) was implemented to patients with responsive disease. The primary endpoint was overall survival. Safety was analyzed in the as-treated population. RESULTS Between June 30, 2017, and April 6, 2021, 224 eligible patients were enrolled and randomly assigned to 54 Gy (n = 108) or 45 Gy (n = 116). Median follow-up for the primary analysis was 45 months (IQR 41-48). Median overall survival was significantly improved in the 54 Gy group (62.4 months) compared with the 45 Gy group (43.1 months; p = 0.001). Median progression-free survival was significantly improved in the 54 Gy group (30.5 months) compared with the 45 Gy group (16.7 months; p = 0.044). The most common grade 3-4 adverse events were neutropenia (30 [28%] of 108 patients in the 54 Gy group vs 27 [23%] of 116 patients in the 45 Gy group), neutropenic infections (6 [6%] vs 2 [2%]), thrombocytopenia (13 [12%] vs 12 [10%]), anemia (6 [6%] vs 4 [3%]), and esophagitis (1 [1%] vs 3 [3%]). Treatment-related serious adverse events occurred in 9 [8%] patients in the 54 Gy group and 16 [14%] patients in the 45 Gy group. There were one treatment-related deaths in 54 Gy group (myocardial infarction). CONCLUSION Compared with standard thoracic radiotherapy dose of 45 Gy, the high dose of 54 Gy improved overall survival and progression-free survival without increasing toxicities in patients with LS-SCLC, supporting twice-daily hyperfractionated thoracic radiotherapy of 54 Gy with concurrent chemotherapy is an alternative treatment option for LS-SCLC. This study is complete and registered with ClinicalTrials.gov, NCT03214003.
Collapse
Affiliation(s)
- J Yu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - L Jiang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - L Zhao
- Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University. ty, Xi'an, China
| | - X Wang
- Department of Radiation Oncology, Anyang Cancer Hospital, Anyang, China
| | - X Yang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Beijing, China
| | - D Yang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - M Zhuo
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Beijing, China
| | - H Chen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Beijing, China
| | - Y D Zhao
- Department of Radiation Oncology, Anyang Tumor Hospital, Anyang, China
| | - F Zhou
- Yantai Yuhuangding Hospital, Yantai, China
| | - Q Li
- Ordos School of Clinical Medicine I.M.M.U, Ordos, China
| | - Z Zhu
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - L Chu
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - Z Ma
- Chifeng Affiliated Hospital, Chifeng, China
| | - Q Wang
- Department of Radiation Oncology, Sichuan Cancer Hospital and Institution, Chengdu, China
| | - Y Qu
- Liaoning cancer hospital & institute, Shenyang, China
| | - W Huang
- Shandong Cancer Hospital & Institute, Jinan, Shandong, China
| | - M Zhang
- Department of Radiation Oncology, Peking University People's Hospital, Beijing, China; Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China
| | - T Gu
- The First Hospital of Qinhuangdao, Qinhuangdao, China
| | - S Liu
- Jilin Provincial Cancer Hospital, Changchun, China
| | - Y Yang
- Jilin Provincial Cancer Hospital, Changchun, China
| | - J Yang
- Department of Oncology, The first Affiliated Hospital of Xinxiang Medical University, Weihui, China
| | - H Yu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - R Yu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - J Zhao
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, China., Beijing, China
| | - A Shi
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China
| |
Collapse
|
3
|
Zhang J, Gao J, Jiang S, Zhou Y, Xu D, Yang X, Chu L, Chu X, Ni J, Zhu Z. Oligo-Residual Disease in PD-1/PD-L1 Inhibitors Treated Metastatic Non-Small Cell Lung Cancer: Incidence, Pattern of Failure and Clinical Value of Local Consolidative Therapy. Int J Radiat Oncol Biol Phys 2023; 117:e80. [PMID: 37786187 DOI: 10.1016/j.ijrobp.2023.06.826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Growing numbers of clinical trials are testing the efficacy of incorporating local therapy into programmed death receptor (ligand) 1 (PD-1/PD-L1) inhibitors in metastatic non-small cell lung cancer (NSCLC), but the optimal timing and patient selection are still controversial. We aimed to examine the patterns of maximum tumor response and treatment failure in PD-1/PD-L1 inhibitor-treated NSCLC, and explore the potential clinical value of local consolidative therapy (LCT) in those with oligo-residual disease (ORD). MATERIALS/METHODS Metastatic NSCLC treated with PD-1/PD-L1 inhibitors in three academic centers from May 2018 to December 2021 were retrospectively reviewed and those derived clinical benefit, defined as having objective response or durable stable disease lasting≥6months, were finally enrolled. Patterns of tumor response and treatment failure were extensively analyzed. ORD was defined as residual tumor distribution limited to 3 organs and 5 lesions, otherwise was defined as multiple residual disease (MRD). Local therapies targeting the residual tumor lesions performed after PD-1/PD-L1 inhibitors initiation and before initial disease progression, were considered as LCT. The primary endpoints were the overall survival (OS) and progression-free survival (PFS). RESULTS Of the 318 patients enrolled, ORD and MRD were documented in 122 (38.4%) and 196 (61.6%) patients, respectively. Those who developed ORD had a significantly longer OS than those with MRD (p = 0.006). The median time to best response was 4 months and more than 50% of the initial disease progression developed only from the residual tumor lesions, providing the preliminary rationale of LCT. Among the 122 patients with ORD, those receiving LCT (n = 39) had significantly longer PFS (p = 0.04) and OS (p<0.001) than those without LCT. Moreover, LCT remained one of the independent predictors of improved PFS and OS after Cox analyses. CONCLUSION Local consolidative therapy seems to be feasible and may provide extra survival benefit for metastatic NSCLC patients with oligo-residual disease after PD-1/PD-L1 inhibitor treatment.
Collapse
Affiliation(s)
- J Zhang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China, Shanghai, China
| | - J Gao
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China, Shanghai, China
| | - S Jiang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China, Shanghai, China
| | - Y Zhou
- Shanghai Medical College, Fudan University, Shanghai, China
| | - D Xu
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China
| | - X Yang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - L Chu
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - X Chu
- Fudan University Shanghai Cancer Center, Shanghai, China
| | - J Ni
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - Z Zhu
- Fudan University Shanghai Cancer Center, Shanghai, China
| |
Collapse
|
4
|
Chu L, Gong Z, Wang W, Han GZ. Origin of the OAS-RNase L innate immune pathway before the rise of jawed vertebrates via molecular tinkering. Proc Natl Acad Sci U S A 2023; 120:e2304687120. [PMID: 37487089 PMCID: PMC10400998 DOI: 10.1073/pnas.2304687120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 06/26/2023] [Indexed: 07/26/2023] Open
Abstract
Discriminating self from nonself is fundamental to immunity. Yet, it remains largely elusive how the mechanisms of self and nonself discrimination originated. Sensing double-stranded RNA as nonself, the 2',5'-oligoadenylate synthetase (OAS)-ribonuclease L (RNase L) pathway represents a crucial component of innate immunity. Here, we combine phylogenomic and functional analyses to show that the functional OAS-RNase L pathway likely originated through tinkering with preexisting proteins before the rise of jawed vertebrates during or before the Silurian period (444 to 419 Mya). Multiple concerted losses of OAS and RNase L occurred during the evolution of jawed vertebrates, further supporting the ancient coupling between OAS and RNase L. Moreover, both OAS and RNase L genes evolved under episodic positive selection across jawed vertebrates, suggesting a long-running evolutionary arms race between the OAS-RNase L pathway and microbes. Our findings illuminate how an innate immune pathway originated via molecular tinkering.
Collapse
Affiliation(s)
- Lingyu Chu
- College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu210023, China
| | - Zhen Gong
- College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu210023, China
| | - Wenqiang Wang
- College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu210023, China
| | - Guan-Zhu Han
- College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu210023, China
| |
Collapse
|
5
|
Chu L, Su F, Han GZ, Wang J. Jawless vertebrates do not escape retrovirus infection. Virology 2023; 583:52-55. [PMID: 37148648 DOI: 10.1016/j.virol.2023.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 04/14/2023] [Accepted: 04/25/2023] [Indexed: 05/08/2023]
Abstract
On occasion, retroviruses infect the genome of germline cell, forming endogenous retroviruses (ERVs), which provide molecular fossils for studying the deep evolution of retroviruses. While ERVs have been extensively characterized in the genomes of jawed vertebrates, much remains contentious and unexplored about the diversity and evolution of ERVs within jawless vertebrates. Here, we report the discovery of a novel ERV lineage, designated EbuERVs, in the genome of a hagfish Eptatretus burgeri. Phylogenetic analyses show that EbuERVs pertain to epsilon-retroviruses and might have derived from cross-species transmission from jawed vertebrates. EbuERVs are estimated to have invaded in the hagfish genome at least tens of millions of years ago. Evolutionary dynamics analyses indicate that EbuERVs might have experienced one proliferation peak and have been not active in transposition anymore. However, some EbuERVs can transcribe in embryo and might serve as lncRNA. Overall, these findings expand the distribution of retroviruses from jawed vertebrates to jawless vertebrates.
Collapse
Affiliation(s)
- Lingyu Chu
- Jiangsu Key Laboratory for Microbes and Functional Genomics, College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu, 210023, China
| | - Fang Su
- Jiangsu Key Laboratory for Microbes and Functional Genomics, College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu, 210023, China
| | - Guan-Zhu Han
- Jiangsu Key Laboratory for Microbes and Functional Genomics, College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu, 210023, China.
| | - Jianhua Wang
- Jiangsu Key Laboratory for Microbes and Functional Genomics, College of Life Sciences, Nanjing Normal University, Nanjing, Jiangsu, 210023, China.
| |
Collapse
|
6
|
Aguilar L, Delgado A, Grandin E, Quintero P, Fleming L, Motiwala S, Sriwattanakomen R, Ho J, Lee C, Malinn A, Frias S, Nicole B, Chu L, Garan A, Sabe M. LVAD as a Bridge to Candidacy in a Patient with Left Ventricular Noncompaction Cardiomyopathy Complicated by RHF. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
7
|
Gupta P, Gold S, Chu L, Amos S, Stevenson MO, Yeung H, Tangpricha V. Persistence of gender affirming hormone therapy in transgender adults: a single center retrospective cohort study. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00644-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
8
|
Chu L, Supapannachart K, Chen S, Yeung H. 329 Financial toxicity and skin cancer care in the US: Population-based survey from 2011-2018. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Case K, Thompson E, Barron J, Radi R, Chu L, Yeung H. 385 Determinants of antibiotic stewardship for acne: A pilot survey of key stakeholders. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Pichon S, Moureau A, Petit C, Chu L, Essink B, Muse D, Saleh J, Guinet-Morlot F, Minutello AM. Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study. Vaccine 2022; 40:4780-4787. [PMID: 35778281 DOI: 10.1016/j.vaccine.2022.06.040] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 06/10/2022] [Accepted: 06/12/2022] [Indexed: 10/17/2022]
Abstract
A serum-free, highly purified Vero cell rabies vaccine (PVRV-NG) is under development. We previously demonstrated that pre-exposure prophylaxis (PrEP) with PVRV-NG had a satisfactory safety profile and was immunogenically non-inferior to the licensed purified Vero cell rabies vaccine in adults. Here, we evaluated the safety and immunogenic non-inferiority of PrEP with PVRV-NG compared to the licensed human diploid cell vaccine (HDCV) in healthy adults (NCT01784874). Participants received three vaccinations (days 0, 7, and 28) as PrEP with or without a booster injection after 12 months. Rabies virus neutralising antibodies (RVNA) were evaluated on days 0, 28 (subgroup only), and 42, and Months 6, 12, and 12 + 14 days (booster group only). Non-inferiority (first primary objective) was based on the proportion of participants with RVNA titres ≥ 0.5 IU/mL (World Health Organization criteria for seroconversion) on day 42, expected to be ≥ 99% (second primary objective). Safety was evaluated after each dose and monitored throughout the study. At day 42, PVRV-NG was non-inferior to HDCV and the first primary objective was met; seroconversion was observed for 98.3% of PVRV-NG recipients and 99.1% of HDCV recipients. As < 99% of participants in the PVRV-NG group had RVNA titres ≥ 0.5 IU/mL, the second primary objective was not met. Booster vaccination produced a strong increase in RVNA titres for all groups, primed with PVRV-NG or HDCV. RVNA geometric mean titres tended to be higher for HDCV than PVRV-NG primary vaccine recipients. In a complementary evaluation using alternative criteria for seroconversion (complete virus neutralization at 1:5 serum dilution), 99.6% and 100% of participants in the PVRV-NG and HDCV groups, respectively, achieved seroconversion across the vaccine groups. No major safety concerns were observed during the study. PVRV-NG was well tolerated, with a similar safety profile to HDCV in terms of incidence, duration, and severity of adverse events after primary and booster vaccinations. ClinicalTrials.gov number: NCT01784874.
Collapse
Affiliation(s)
- Sylvie Pichon
- Sanofi, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France.
| | - Annick Moureau
- Sanofi, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France
| | - Celine Petit
- Sanofi, 1541 Avenue Marcel Mérieux, 69280 Marcy-l'Étoile, France
| | - L Chu
- Benchmark Research, 1015 East 32(nd) Street, Austin, TX 78705, USA
| | - B Essink
- Meridian Clinical Research, 3319 North 107(th) Street, Omaha, NE 68134, USA
| | - D Muse
- Jean Brown Research, 1045 East 3900 South, Suite 100, Salt Lake City, UT 8412, USA
| | - J Saleh
- Northern Californian Clinical Research Center, 3652 Eureka Way, Redding, CA 96001, USA
| | | | | |
Collapse
|
11
|
Chu L, Wang L, Wu Y, Yang H, Wang W, Lu Q, Deng H. Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis. Actas Dermosifiliogr 2022; 113:T244-T253. [PMID: 35331446 DOI: 10.1016/j.ad.2021.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 10/09/2021] [Accepted: 10/11/2021] [Indexed: 10/20/2022] Open
Abstract
BACKGROUND Prurigo nodularis (PN) as an extremely pruritic and hyperplastic chronic dermatosis induces psychologically and physiologically stressful responses. PN-induced responses in the hypothalamic-pituitary-adrenal, hypothalamic-pituitary-gonadal axes and endocannabinoid system are abnormal. Extant studies on the PN's pathogenesis mostly focused on the PN's psychological responses. To date, the PN's physiological responses remain not been fully uncovered yet. OBJECTIVES To investigate the PN-induced physiological responses via the levels of 5steroids and 2endocannabinoids combined with their ratios in plasma and examine the association between the psychological and physiological responses. MATERIALS AND METHODS Thirty-six patients with PN, 36 age- and gender-matched healthy controls were recruited. The PN's psychological symptoms including pruritus severity, pain and life quality were measured with the visual analogue scale, the prurigo score index, numerical rating scale, verbal rating scale and dermatology life quality index. Their concentrations of steroids and endocannabinoids were determined with liquid chromatography-tandem mass spectrometry. RESULTS Compared to controls, the PN patients showed lower plasma levels in cortisol, cortisone, N-arachidonoyl-ethanolamine, and the ratio of DHEA to 1-arachydonoyl glycerol (1-AG), which negatively moderately and over correlated with PN's symptoms, especially with the pruritus severity. Additionally, the PN patients exhibited higher levels in the ratios of testosterone and 1-AG to cortisol, which positively moderately and over correlated with pruritus severity. Thus, the 7biomarkers would be sensitive and reliable biomarkers for assessing the pruritus severity of PN because they met the screening criteria that the biomarkers show intergroup differences and showed moderate or over correlation with the pruritus severity of PN. CONCLUSIONS To the best of our knowledge, this is the first study exploring PN-induced physiological responses. The findigs suggest that alterations in these 3endocrine systems may lead to new insights to psychological mechanisms and responses to PN.
Collapse
Affiliation(s)
- L Chu
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China
| | - L Wang
- Department of Rehabilitation Medicine, the Third Medical Centre, Chinese PLA General Hospital, Pekín, China
| | - Y Wu
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China
| | - H Yang
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China
| | - W Wang
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China
| | - Q Lu
- Department of Prescription Science, School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang 050200, Hebei, China.
| | - H Deng
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China.
| |
Collapse
|
12
|
Chu L, Wang LK, Wu Y, Yang H, Wang W, Lu Q, Deng H. Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis. Actas Dermosifiliogr 2022; 113:244-253. [PMID: 35282859 DOI: 10.1016/j.ad.2022.02.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Accepted: 10/11/2021] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Prurigo nodularis (PN) as an extremely pruritic and hyperplastic chronic dermatosis induces psychologically and physiologically stressful responses. PN-induced responses in the hypothalamic-pituitary-adrenal (HPA), hypothalamic-pituitary-gonadal (HPG) axes and endocannabinoid system (ECS) are abnormal. Extant studies on the PN's pathogenesis mostly focused on the PN's psychological responses. To date, the PN's physiological responses remain not been fully uncovered yet. OBJECTIVES To investigate the PN-induced physiological responses via the levels of five steroids and two endocannabinoids combined with their ratios in plasma and examine the association between the psychological and physiological responses. MATERIALS AND METHODS Thirty-six patients with PN, 36 age- and gender-matched healthy controls were recruited. The PN's psychological symptoms including pruritus severity, pain and life quality were measured with the visual analog scale, the prurigo score index, numerical rating scale, verbal rating scale and dermatology life quality index. Their concentrations of steroids and endocannabinoids were determined with liquid chromatography-tandem mass spectrometry. RESULTS Compared to controls, the PN patients showed lower plasma levels in cortisol, cortisone, N-arachidonoyl-ethanolamine (AEA), and the ratio of DHEA to 1-arachydonoyl glycerol (1-AG), which negatively moderately and over correlated with PN's symptoms, especially with the pruritus severity. Additionally, the PN patients exhibited higher levels in the ratios of testosterone and 1-AG to cortisol, which positively moderately and over correlated with pruritus severity. Thus, the seven biomarkers would be sensitive and reliable biomarkers for assessing the pruritus severity of PN because they met the screening criteria that the biomarkers show intergroup differences and showed moderate or over correlation with the pruritus severity of PN. CONCLUSIONS To the best of our knowledge, this is the first study exploring PN-induced physiological responses. The findings suggest that alterations in these three endocrine systems may lead to new insights to psychological mechanisms and responses to prurigo nodularis.
Collapse
Affiliation(s)
- L Chu
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China
| | - L-K Wang
- Department of Rehabilitation Medicine, the Third Medical Centre, Chinese PLA General Hospital, Beijing, China
| | - Y Wu
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China
| | - H Yang
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China
| | - W Wang
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China
| | - Q Lu
- Department of Prescription Science, School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China.
| | - H Deng
- School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China; Key Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China; Institute of Child Development and Education, Southeast University, Nanjing, China.
| |
Collapse
|
13
|
Gao HY, Wan C, Sun FD, Wang SY, Chu L, Yuan Y, Wang P, Yu XQ, Liu WY, Dong HF, Yang XD. [Effect of Echinococcus granulosus hydatid cyst fluid protein on allergic rhinitis induced by ovalbumin in mice]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2022; 34:158-162. [PMID: 35537837 DOI: 10.16250/j.32.1374.2021276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
OBJECTIVE To investigate the protective effect of Echinococcus granulosus hydatid cyst fluid protein (HCFP) on ovalbumin (OVA)-induced allergic rhinitis (AR) in mice. METHODS Twenty-four BALB/c mice at ages of 8 to 10 weeks, each weighing approximately 20 g, were randomly divided into four groups, including groups A (blank control group), B (blank intervention group), C (AR model group) and D (AR+HCFP intervention group), with 6 mice in each group. On days 0, 2, 4, 6, 8, 10 and 12, mice in groups A, B, C and D were injected with 200 μL sterile phosphate buffered saline (PBS), 200 μL sterile PBS containing 20 μg HCFP, 200 μL sterile PBS containing 50 μg OVA and 5 mg Al(OH)3 gel, and 200 μL sterile PBS containing 50 μg OVA, 5 mg Al(OH)3 gel and 20 μg HCFP, respectively. On days 14 to 20, mice in groups A, B, C and D were administered with 40 μL sterile PBS, 40 μL sterile PBS containing 20 μg HCFP, 40 μL sterile PBS containing 2 mg OVA and 40 μL sterile PBS containing 2 mg OVA and 20 μL HCFP by nasal drop, respectively. Mouse behavioral changes were observed and behavioral scores were estimated. The serum levels of interferon-γ (IFN-γ), interleukin-4 (IL-4), IL-5, IL-10, transforming growth factor-β (TGF-β) and OVA-specific IgE antibody (OVA-sIgE) were measured using enzyme-linked immunosorbent assay (ELISA), and the pathological changes of mouse nasal mucosa were observed by hematoxylin and eosin (HE) staining. RESULTS The mean behavioral score was significantly greater in Group C (6.83 ± 0.50) than in groups A (1.17 ± 0.52) and B (1.33 ± 0.52) (P < 0.05), while a lower mean behavioral score was estimated in Group D (3.50 ± 0.50) than in Group C (P < 0.05). There were significant differences among the groups in terms of serum IFN-γ (F = 4.08, P < 0.05), IL-4 (F = 275.90, P < 0.05), IL-5 (F = 96.82, P < 0.05), IL-10 (F = 77.67, P < 0.05), TGF-β (F = 9.98, P < 0.05) and OVA-sIgE levels (F = 44.69, P < 0.05). The serum IFN-γ level was significantly lower in Group C than in groups A, B and C (P < 0.05), and the serum levels of IL-4, IL-5 and OVA-sIgE were significantly higher in Group C than in groups A, B and C (P < 0.05), while the serum IL-10 and TGF-β levels were significantly greater in Group D than in Group C (P < 0.05). Microscopy showed apparent loss of nasal mucosa cilia, increased number and enlargement of goblet cells, interstitial edema and submucous vascular dilation in Group C, while the pathological changes of nasal mucosa were alleviated in Group D relative to Group C. CONCLUSIONS E. granulosus HCFP has a protective activity against OVA-induced allergic rhinitis in mice.
Collapse
Affiliation(s)
- H Y Gao
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233000, China
- Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, China
- Co-first authors
| | - C Wan
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233000, China
- Department of Microbiology and Parasitology, Bengbu Medical College, Bengbu, Anhui 233000, China
- Co-first authors
| | - F D Sun
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, China
| | - S Y Wang
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233000, China
- Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, China
| | - L Chu
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, China
| | - Y Yuan
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233000, China
- Department of Basic Medical Sciences, Bengbu Medical College, China
| | - P Wang
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233000, China
| | - X Q Yu
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233000, China
| | - W Y Liu
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233000, China
| | - H F Dong
- Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233000, China
| | - X D Yang
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, Bengbu, Anhui 233000, China
- Department of Microbiology and Parasitology, Bengbu Medical College, Bengbu, Anhui 233000, China
| |
Collapse
|
14
|
Wang SY, Yang XD, Gao HY, Xing JY, Hu Q, Huang TT, Wu P, Zhao YT, Liu HW, Liu WY, Wang HN, Zhou R, Chu L. [Analysis of components of proteins from Echinococcus granulosus cyst fluid]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2021; 33:476-482. [PMID: 34791845 DOI: 10.16250/j.32.1374.2021111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To analyze the components of proteins from Echinococcus granulosus cyst fluid using the shotgun method, and to identify the active components with potential regulatory effects for immune dysregulation diseases. METHODS The E. granulosus cyst fluid was collected aseptically from the hepatic cysts of patients with cystic echinococcosis, and characterized by liquid chromatography (LC) tandem mass spectrometry (MS/MS) following digestion with trypsin. The protein data were searched using the software MaxQuant version 1.6.1.0 and the cellular components, molecular functions, and biological processes of the identified proteins were analyzed using the Gene Ontology (GO) method. RESULTS The E. granulosus cyst fluid separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) had a relative molecular mass of 25 to 70 kDa. LS-MS/MS analysis identified 37 proteins, including 32 known proteins and 5 unknown proteins. At least 4 proteins were preliminarily found to exhibit potential regulatory effects for immune dysregulation diseases, including antigen B, glutathione-S-transferase (GST), thioredoxin peroxidase (TPX) and malate dehydrogenase (MDH). GO enrichment analysis showed that the identified proteins had 149 molecular functions and were involved in 341 biological processes. CONCLUSIONS E. granulosus cyst fluid has a variety of protein components, and four known proteins are preliminarily identified to be associated with immune dysregulation diseases.
Collapse
Affiliation(s)
- S Y Wang
- Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China.,Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China.,Co-first authors
| | - X D Yang
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China.,Department of Microbiology and Parasitology, Bengbu Medical College, China.,Co-first authors
| | - H Y Gao
- Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China.,Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - J Y Xing
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - Q Hu
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - T T Huang
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - P Wu
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - Y T Zhao
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - H W Liu
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - W Y Liu
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - H N Wang
- Anhui Key Laboratory of Infection and Immunity, Bengbu Medical College, China
| | - R Zhou
- Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China
| | - L Chu
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, China
| |
Collapse
|
15
|
Ding T, Liu C, Huang B, Chu L, Wei L, Lin Y, Luo Y, Zhang B, Hong C, Xu Y, Peng Y. A Survival Prediction Nomogram for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery. Cancer Manag Res 2021; 13:7771-7782. [PMID: 34675672 PMCID: PMC8519412 DOI: 10.2147/cmar.s329687] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 09/23/2021] [Indexed: 02/05/2023] Open
Abstract
Background Neoadjuvant chemoradiotherapy (NCRT) followed by surgery is a component of the standard treatment for resectable locally advanced esophageal squamous cell carcinoma (ESCC), and the parameters for survival prediction are not clear yet. Our study aimed to construct a survival prediction nomogram for ESCC with NCRT followed by surgery. Methods We analyzed hematological parameters and related-derivative indexes from 122 ESCC patients treated with NCRT followed by surgery. Univariate and multivariate Cox survival analyses were performed to identify independent prognostic factors to establish a nomogram and predict overall survival (OS). The predictive value of the nomogram for OS was evaluated by the concordance index (C-index), decision curve analysis (DCA), the clinical impact curve (CIC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results The pretreatment nutritional candidate, prognostic nutrition index, inflammation-related absolute monocyte count and TNM staging were entered into the nomogram for ESCC with NCRT followed by surgery. The C-index of the nomogram for OS was 0.790 (95% CI = 0.688–0.893), which was higher than that of TNM staging (0.681; 95% CI = 0.565–0.798, P = 0.026). The DCA, CIC, NRI, and IDI of the nomogram showed moderate improvement in predicting survival. Based on the cut point calculated according to the constructed nomogram, the high-risk group had poorer OS than that of the low-risk group (P < 0.05). Conclusion A novel nomogram based on nutrition- and inflammation-related indicators might help predict the survival of ESCC treated with NCRT followed by surgery.
Collapse
Affiliation(s)
- Tianyan Ding
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Cantong Liu
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Binliang Huang
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Lingyu Chu
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Laifeng Wei
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Yiwei Lin
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Yun Luo
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Biao Zhang
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Chaoqun Hong
- Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China
| | - Yiwei Xu
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| | - Yuhui Peng
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, People's Republic of China.,Precision Medicine Research Center, Shantou University Medical College, Shantou, People's Republic of China
| |
Collapse
|
16
|
Zhu B, Chu L, Yang F, Fwa TF. Improved approach for evaluating saturated surface infiltration capacity of interlocking-block permeable pavements. J Environ Manage 2021; 295:113087. [PMID: 34175508 DOI: 10.1016/j.jenvman.2021.113087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 06/13/2021] [Accepted: 06/13/2021] [Indexed: 06/13/2023]
Abstract
Different infiltration tests of permeable pavements provide different measurements of the infiltration capacity. These measurements often do not represent the fundamental flow properties, and hence cannot be directly compared. This presents an undesirable obstacle to the sharing of experience and to obtaining a better understanding of the infiltration performances of different permeable pavements. This problem is especially acute in the case of interlocking-block permeable pavements (IBPPs), owing to the presence of joints and the different sizes, shapes, and laying patterns of paving blocks. To overcome this problem, the present study proposed a new approach for evaluating the infiltration capacity of an IBPP while retaining the same measuring devices in use today. This approach makes use of a finite-volume computational fluid dynamic method to develop a simulation model for an infiltration test. Once calibrated to define the hydraulic parameters of the IBPP being tested, the model can be applied to calculate the saturated infiltration capacity of the IBPP under actual rainfall conditions. The model also permits the calculation of a conventional infiltration capacity measurement, such as the average infiltration rate in mm/h as measured by a particular infiltration test, or the time required to drain the tested water depth. Thus, the proposed approach provides a meaningful common basis for comparing the infiltration capacities of different permeable pavements, including porous asphalt, pervious concrete, and IBPPs.
Collapse
Affiliation(s)
- B Zhu
- School of Highway, Chang'an University, South Erhuan Middle Section, Xi'an, 710064, China
| | - L Chu
- School of Highway, Chang'an University, South Erhuan Middle Section, Xi'an, 710064, China.
| | - Fengyi Yang
- School of Highway, Chang'an University, South Erhuan Middle Section, Xi'an, 710064, China
| | - T F Fwa
- School of Highway, Chang'an University, South Erhuan Middle Section, Xi'an, 710064, China; Department of Civil & Environmental Engineering, National University of Singapore, 10 Kent Ridge Crescent, 119260, Singapore
| |
Collapse
|
17
|
Cao D, Chu L, Xu Z, Gong J, Deng R, Wang B, Zhou S. Visfatin facilitates gastric cancer malignancy by targeting snai1 via the NF-κB signaling. Hum Exp Toxicol 2021; 40:1646-1655. [PMID: 33823623 DOI: 10.1177/09603271211006168] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Visfatin acts as an oncogenic factor in numerous tumors through a variety of cellular processes. Visfatin has been revealed to promote cell migration and invasion in gastric cancer (GC). Snai1 is a well-known regulator of EMT process in cancers. However, the relationship between visfatin and snai1 in GC remains unclear. The current study aimed to explore the role of visfatin in GC. METHODS The RT-qPCR and western blot analysis were used to measure RNA and protein levels, respectively. The cell migration and invasion were tested by Trans-well assays and western blot analysis. RESULTS Visfatin showed upregulation in GC cells. Additionally, Visfatin with increasing concentration facilitated epithelial-mesenchymal transition (EMT) process by increasing E-cadherin and reducing N-cadherin and Vimentin protein levels in GC cells. Moreover, endogenous overexpression and knockdown of visfatin promoted and inhibited migratory and invasive abilities of GC cells, respectively. Then, we found that snai1 protein level was positively regulated by visfatin in GC cells. In addition, visfatin activated the NF-κB signaling to modulate snai1 protein expression. Furthermore, the silencing of snai1 counteracted the promotive impact of visfatin on cell migration, invasion and EMT process in GC. CONCLUSION Visfatin facilitates cell migration, invasion and EMT process by targeting snai1 via the NF-κB signaling, which provides a potential insight for the treatment of GC.
Collapse
Affiliation(s)
- D Cao
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - L Chu
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - Z Xu
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - J Gong
- Department of GI Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - R Deng
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - B Wang
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| | - S Zhou
- Department of General Surgery, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
| |
Collapse
|
18
|
Peng J, Chu L, Wang T, Fwa TF. Analysis of vehicle skidding potential on horizontal curves. Accid Anal Prev 2021; 152:105960. [PMID: 33540346 DOI: 10.1016/j.aap.2020.105960] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2020] [Revised: 12/08/2020] [Accepted: 12/16/2020] [Indexed: 06/12/2023]
Abstract
High crash rates on horizontal curves during wet weather are a major road safety concern. Among the various causes of crashes on horizontal curves, wet-weather skidding is a major contributing factor. This study analyzed the mechanisms of three possible modes of vehicle skidding on horizontal curves based on theories of mechanics. The three modes of skidding analyzed were: (i) forward skidding of front steering wheel, (ii) sideway skidding of front steering wheel, and (iii) sideway skidding of rear wheel. The main objective was to provide useful information to researchers and practitioners in identifying the important factors that contribute to horizontal curve crashes. A computer simulation procedure was developed to evaluate the maximum safe vehicle speeds against the three modes of skidding on wet horizontal curved pavements. This offers a much improved method for skidding potential evaluation compared to the conventional approximate method using estimated coefficient of friction. The skidding potential of a vehicle is defined as the difference between its speed and the maximum safe speed against skidding. The smaller the difference, the higher is the skidding potential. The relative magnitudes of skidding potential for the three skidding modes were considered for different operating conditions. Different operating conditions were represented by different values of pavement curve radii, super-elevations, and wet-weather conditions represented by the thickness of pavement surface water-film. The analysis identified five key factors that affect the skidding potential of vehicles negotiating a horizontal curve. They are: vehicle speed, curve radius, superelevation, water film thickness and pavement skid resistance state.
Collapse
Affiliation(s)
- Jia Peng
- School of Highway, Chang'an University, Xi'an, China
| | - L Chu
- School of Highway, Chang'an University, China
| | - Tangjie Wang
- School of Highway, Chang'an University, Xi'an, China
| | - T F Fwa
- School of Highway, Chang'an University, China; National University of Singapore, Singapore.
| |
Collapse
|
19
|
Liao FF, Chu L. [Laryngeal inflammatory myofibroblastic tumor with malignant change: a case report]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2020; 55:704-706. [PMID: 32668884 DOI: 10.3760/cma.j.cn115330-20191226-00782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- F F Liao
- Department of Pathology, the Third Xiangya Hospital of Central South University, Changsha 410013, China
| | - L Chu
- Department of Pathology, the Third Xiangya Hospital of Central South University, Changsha 410013, China
| |
Collapse
|
20
|
Li HY, Jiang FQ, Chu L, Wei X. Long non-coding RNA BLACAT1 inhibits prostate cancer cell proliferation through sponging miR-361. Eur Rev Med Pharmacol Sci 2020; 24:74-85. [PMID: 31957820 DOI: 10.26355/eurrev_202001_19897] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE LncRNAs play a key role in the development and progression of prostate cancer. In this study, the effects of the lncRNA BLACAT1 in prostate cancer were investigated. PATIENTS AND METHODS Real-time PCR was used to detect the expression of BLACAT1 and miR-361 in prostate cancer tissues and adjacent normal tissues (n=25). The function of BLACAT1 was detected through proliferation assay and apoptosis assay. The interaction between BLACAT1 and miR-361 in prostate cancer was studied by luciferase assay, RNA immunoprecipitation assay and chromatin immunoprecipitation analysis were performed to detect the BLACAT1 binding proteins. The xenograft mice experiment was performed to further confirm the functional significance of lncRNA BLACAT1 in vivo. RESULTS In patient samples and prostate cancer cell lines, BLACAT1 was down-regulated and inversely proportional to DNMT1, HDAC1, EZH2, MDM2 and miR-361 expression. Treatment with 5-azacytidine and chidamide enhanced BLACAT1 expression and decreased the levels of miR-361. The BALCAT1 promoter was methylated in prostate cancer tissue and found to interact with miR-361 via luciferase assays. BLACAT1 bound to EZH2, DNMT1 and HDAC1. ChIP-seq analysis revealed that HDAC1 interacts with STAT3, while EZH2 interacts with the mitogen-activated protein kinase (MAPK) promoter. CONCLUSIONS Two regulatory axes of BLACAT1-EZH2-MAPK and BLACAT1-HDAC1-STAT3 were identified to be associated with the progression of prostate cancer. Both chidamide and 5-azacytidine represent promising therapeutic options in prostate cancer treatment.
Collapse
Affiliation(s)
- H-Y Li
- Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, People's Republic of China.
| | | | | | | |
Collapse
|
21
|
Ye L, Chu L, Wang S, Zhou L, Zhu Z. Mapping Of Retroperitoneal Lymph Nodal Metastases After Surgery For Lower Thoracic Esophageal Cancer: A Recommendation For Clinical Target Volume. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Song S, Sun C, Zhou J, Chu L. Corrigendum to “Flavonoids as human carboxylesterase 2 inhibitors: Inhibition potentials and molecular docking simulations” [Int. J. Biol. Macromol. 131 (2019) 201–208]. Int J Biol Macromol 2020; 157:770-771. [DOI: 10.1016/j.ijbiomac.2020.02.268] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
23
|
Yang JS, Liu P, Liu JJ, Chu L, Li J, Chen C, Yan L, Liu TJ, Chen H, Hao DJ. Suberoylanilide hydroxamic acid attenuates epidural fibrosis via inhibiting myofibroblast differentiation and increasing fibroblast apoptosis. Eur Rev Med Pharmacol Sci 2020; 24:5726-5733. [PMID: 32495908 DOI: 10.26355/eurrev_202005_21364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Epidural fibrosis represents a fatal stage of failed back surgery syndrome (FBSS) of known and idiopathic etiology, but no valid therapy is presently available. Previous evidence demonstrated that suberoylanilide hydroxamic acid (SAHA), a histone deacetylases inhibitor, has antifibrotic and anti-inflammatory potential. Current studies have proved that SAHA inhibits myofibroblast differentiation and increases fibroblast apoptosis to attenuate epidural fibrosis. The purpose of this study was to investigate the effect and mechanism of SAHA on repressing epidural fibrosis. PATIENTS AND METHODS First, the levels of acetylation of histone and α-tubulin in adult human fibroblasts (AHF) and human epidural fibroblasts (HEF) were analyzed following SAHA and transforming growth factor-β(TGF-β) treatment. Then, mRNA and protein obtained from human fibroblasts following TGF-β activation and SAHA treatment in vitro culture were used to test the influence of SAHA on the activation and apoptosis of fibroblasts, so as to further explore the related mechanism of SAHA. Then, a laminectomy model was established in rats to observe the therapeutic effect of SAHA on epidural scar tissue. RESULTS The present research proved that the increases of HDAC 3 and α-tubulin were observed in AHF and HEF after TGF-β administration, but SAHA decreased HDAC 3 and α-tubulin expressions. In addition, cell study demonstrated that SAHA inhibited fibroblast activation via decreasing TGF-β function and accelerated apoptosis by promoting cleaved-caspase-3. In the epidural fibrosis model, it was found that SAHA weakened scar hyperplasia and collagen deposition, and effectively inhibited the process of epidural fibrosis. CONCLUSIONS These results indicated that SAHA inhibited HDAC 3 expression, decreased TGF-β effect, and enhanced caspase-3 in fibroblasts, leading reduction of myofibroblast activation and apoptosis elevation. Hence, SAHA ameliorated epidural fibrosis development.
Collapse
Affiliation(s)
- J-S Yang
- Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Xie H, Chu L, Wu LQ, Fan XY, Wang P, Ma SY, Zheng DX, Li KL, Chen XZ, Yang XD. [Polarization of bone marrow-derived macrophages induced by recombinant Trichinella spiralis cysteine protease inhibitors in vitro]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2020; 32:181-186. [PMID: 32458608 DOI: 10.16250/j.32.1374.2019245] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To investigate the regulatory role of recombinant Trichinella spiralis cysteine protease inhibitors (rTs-Cys) in induction of polarization of bone marrow-derived macrophages (BMDMs) in vitro. METHODS BMDMs were captured and cultured in conditioned medium for 7 days. Then, mature BMDMs were harvested and assigned into four groups. Cells in Group A (negative control) were given 10 ng/mL IFN-γ combined with 100 ng/mL LPS, cells in Group B (positive control) were treated with IL-4 and IL-10 (at 10 ng/mL both), and cells in Group C (recombinant protein alone) were stimulated with 1 μg/mL rTs-Cys, while cells in Group D (protein co-culture) were simultaneously treated with 1 μg/mL rTs-Cys, 10 ng/mL IFN-γ and 100 ng/mL LPS. Cells and culture supernatant were collected 24 hour post-treatment, and the proportions of F4/80+, CD11b+, CD206+ and CD11c+ cells were detected by flow cytometry. The levels of interleukin IL-6 (IL-6), tumor necrosis factor-α (TNF-α), IL-10 and transforming growth factor-β (TGF-β) in the cell culture supernatant were measured by ELISA and the CD86+ and CD206+ phenotypes were identified by immunofluorescent staining. RESULTS Flow cytometry detected no significant difference in the proportion of F4/80+ CD11b+ CD11c+ cells among the four groups (F = 46.184, P < 0.001), and a lower proportion of F4/80+ CD11b+ CD11c+ cells was seen in groups C and D than in group A (all P values < 0.001). There was a significant difference in the proportion of F4/80+ CD11b+ CD206+ cells among the four groups (F = 11.032, P < 0.001), and a greater proportion of F4/80+ CD11b+ CD206+ cells was seen in groups C and D than in group A (all P values < 0.01). Immunofluorescent staining showed higher CD206+ expression and lower CD86+ expression in groups C and D than in Group A. There were significant differences in the IL-6 and (F = 3.950, P < 0.001) and TNF-α (F = 205.827, P < 0.001) levels in the cell culture supernatants among the four groups, and significantly lower IL-6 and TNF-α levels were measured in groups C and D than in Group A (both P < 0.05). There were significant differences in the IL-10 and (F = 8.274, P < 0.001) and TGF-β (F = 13.559, P < 0.01) levels in the cell culture supernatants among the four groups, and greater IL-10 and TGF-β levels were measured in Group C than in Group A (both P values < 0.01). In addition, the TGF-β level was significantly higher in Group D than in Group A (P < 0.05); however, there was no significant difference in the IL-10 level between groups D and A (P > 0.05). CONCLUSIONS rTs-Cys may induce the polarization of BMDMs to antiinflammatory M2 macrophages in vitro and inhibit the activation of M1 macrophages.
Collapse
Affiliation(s)
- H Xie
- Basic Medical College, Bengbu Medical College, Bengbu 233000, China.,Anhui Key Laboratory of Infection and Immunity, China
| | - L Chu
- The Second Affiliated Hospital of Bengbu Medical College, China
| | - L Q Wu
- Anhui Key Laboratory of Infection and Immunity, China.,The First Affiliated Hospital of Bengbu Medical College, China
| | - X Y Fan
- Anhui Key Laboratory of Infection and Immunity, China
| | - P Wang
- Anhui Key Laboratory of Infection and Immunity, China
| | - S Y Ma
- Anhui Key Laboratory of Infection and Immunity, China
| | - D X Zheng
- Anhui Key Laboratory of Infection and Immunity, China
| | - K L Li
- Anhui Key Laboratory of Infection and Immunity, China
| | - X Z Chen
- Basic Medical College, Bengbu Medical College, Bengbu 233000, China.,Anhui Key Laboratory of Infection and Immunity, China
| | - X D Yang
- Basic Medical College, Bengbu Medical College, Bengbu 233000, China.,Anhui Key Laboratory of Infection and Immunity, China
| |
Collapse
|
25
|
Asad M, Munir F, Xu X, Li M, Jiang Y, Chu L, Yang G. Functional characterization of the cis-regulatory region for the vitellogenin gene in Plutella xylostella. Insect Mol Biol 2020; 29:137-147. [PMID: 31850544 DOI: 10.1111/imb.12632] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 11/23/2019] [Accepted: 12/11/2019] [Indexed: 06/10/2023]
Abstract
The vitellogenin gene promoter (VgP) is an essential cis-regulatory element that plays a significant role in transcription of the vitellogenin (Vg) gene, leading to the production of yolk protein in insects, including lepidopterans. However, the function of VgP is still not clear in Plutella xylostella. Here, we cloned a 5.1 kb DNA fragment of the cis-regulatory region adjacent to the 5' end of the Vg gene of P. xylostella (PxVg). We identified two promoter sites in that 5' upstream sequence of PxVg and performed in vitro analysis of two promoter sequences (PxVgP1, 4.9 kb, and PxVgP2, 2.9 kb) in the embryonic cell line of P. xylostella. PxVgP2 exhibited higher enhanced green fluorescent protein (EGFP) expression, so PxVgP2 was used for in vivo analysis. Strong EGFP fluorescence was observed in adult females and the fat body of females, with low expression in embryos. Our results suggest that PxVgP is an important stage-, tissue- and sex-specific endogenous cis-regulatory element in P. xylostella.
Collapse
Affiliation(s)
- M Asad
- State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, Institute of Applied Ecology, Fujian Agriculture and Forestry University, Fuzhou, China
- Joint International Research Laboratory of Ecological Pest Control, Ministry of Education, Fuzhou, China
- Key Laboratory of Integrated Pest Management for Fujian-Taiwan Crops, Ministry of Agriculture, Fuzhou, China
- Key Laboratory of Green Pest Control, Fujian Province University, Fuzhou, China
| | - F Munir
- State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, Institute of Applied Ecology, Fujian Agriculture and Forestry University, Fuzhou, China
- Joint International Research Laboratory of Ecological Pest Control, Ministry of Education, Fuzhou, China
- Key Laboratory of Integrated Pest Management for Fujian-Taiwan Crops, Ministry of Agriculture, Fuzhou, China
- Key Laboratory of Green Pest Control, Fujian Province University, Fuzhou, China
| | - X Xu
- State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, Institute of Applied Ecology, Fujian Agriculture and Forestry University, Fuzhou, China
- Joint International Research Laboratory of Ecological Pest Control, Ministry of Education, Fuzhou, China
- Key Laboratory of Integrated Pest Management for Fujian-Taiwan Crops, Ministry of Agriculture, Fuzhou, China
- Key Laboratory of Green Pest Control, Fujian Province University, Fuzhou, China
| | - M Li
- State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, Institute of Applied Ecology, Fujian Agriculture and Forestry University, Fuzhou, China
- Joint International Research Laboratory of Ecological Pest Control, Ministry of Education, Fuzhou, China
- Key Laboratory of Integrated Pest Management for Fujian-Taiwan Crops, Ministry of Agriculture, Fuzhou, China
- Key Laboratory of Green Pest Control, Fujian Province University, Fuzhou, China
| | - Y Jiang
- State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, Institute of Applied Ecology, Fujian Agriculture and Forestry University, Fuzhou, China
- Joint International Research Laboratory of Ecological Pest Control, Ministry of Education, Fuzhou, China
- Key Laboratory of Integrated Pest Management for Fujian-Taiwan Crops, Ministry of Agriculture, Fuzhou, China
- Key Laboratory of Green Pest Control, Fujian Province University, Fuzhou, China
| | - L Chu
- State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, Institute of Applied Ecology, Fujian Agriculture and Forestry University, Fuzhou, China
- Joint International Research Laboratory of Ecological Pest Control, Ministry of Education, Fuzhou, China
- Key Laboratory of Integrated Pest Management for Fujian-Taiwan Crops, Ministry of Agriculture, Fuzhou, China
- Key Laboratory of Green Pest Control, Fujian Province University, Fuzhou, China
| | - G Yang
- State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, Institute of Applied Ecology, Fujian Agriculture and Forestry University, Fuzhou, China
- Joint International Research Laboratory of Ecological Pest Control, Ministry of Education, Fuzhou, China
- Key Laboratory of Integrated Pest Management for Fujian-Taiwan Crops, Ministry of Agriculture, Fuzhou, China
- Key Laboratory of Green Pest Control, Fujian Province University, Fuzhou, China
| |
Collapse
|
26
|
Zhou J, Li Y, Cao H, Yang M, Chu L, Li T, Yu Z, Yu R, Qiu B, Wang Q, Li X, Xie J. CATA: a comprehensive chromatin accessibility database for cancer. Database (Oxford) 2020; 2022:6520815. [PMID: 35134148 PMCID: PMC9246274 DOI: 10.1093/database/baab085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Revised: 12/05/2021] [Accepted: 12/29/2021] [Indexed: 11/30/2022]
Abstract
Accessible chromatin refers to the active regions of a chromosome that are bound by many transcription factors (TFs). Changes in chromatin accessibility play a critical role in tumorigenesis. With the emergence of novel methods like Assay for Transposase-accessible Chromatin Sequencing, a sequencing method that maps chromatin-accessible regions (CARs) and enables the computational analysis of TF binding at chromatin-accessible sites, the regulatory landscape in cancer can be dissected. Herein, we developed a comprehensive cancer chromatin accessibility database named CATA, which aims to provide available resources of cancer CARs and to annotate their potential roles in the regulation of genes in a cancer type-specific manner. In this version, CATA stores 2 991 163 CARs from 23 cancer types, binding information of 1398 TFs within the CARs, and provides multiple annotations about these regions, including common single nucleotide polymorphisms (SNPs), risk SNPs, copy number variation, somatic mutations, motif changes, expression quantitative trait loci, methylation and CRISPR/Cas9 target loci. Moreover, CATA supports cancer survival analysis of the CAR-associated genes and provides detailed clinical information of the tumor samples. Database URL: CATA is available at http://www.xiejjlab.bio/cata/.
Collapse
Affiliation(s)
- Jianyuan Zhou
- Central Laboratory of Molecular Biology, Medical College of Jiaying University, 146 Huangtang Road, Meizhou 514031, China
- Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong
- First Medical University, and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan 250000, China
| | | | | | - Min Yang
- Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China
| | - Lingyu Chu
- Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China
| | - Taisong Li
- Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China
| | - Zhengmin Yu
- School of Medical Informatics, Harbin Medical University, Daqing Campus, Daqing 163319, China
| | - Rui Yu
- School of Medical Informatics, Harbin Medical University, Daqing Campus, Daqing 163319, China
| | - Bo Qiu
- Central Laboratory of Molecular Biology, Medical College of Jiaying University, 146 Huangtang Road, Meizhou 514031, China
| | - Qiuyu Wang
- School of Medical Informatics, Harbin Medical University, Daqing Campus, Daqing 163319, China
| | - Xuecang Li
- School of Medical Informatics, Harbin Medical University, Daqing Campus, Daqing 163319, China
| | - Jianjun Xie
- Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou 515041, China
| |
Collapse
|
27
|
Xie Y, Song T, Huo M, Zhang Y, Zhang YY, Ma ZH, Wang N, Zhang JP, Chu L. Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway. Eur Rev Med Pharmacol Sci 2019; 22:5665-5677. [PMID: 30229844 DOI: 10.26355/eurrev_201809_15834] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Rho-associated kinases (ROCKs) are recognized to be involved in many pathophysiological processes caused by hyperglycemia. We performed experiments to evaluate the effects of fasudil, the Rho/ROCK inhibitor, on preventing hepatic fibrosis in type 1 diabetic rats and to elucidate the underlying mechanisms. MATERIALS AND METHODS Sprague-Dawley (SD) rats were randomly divided into five groups: normal control (NC), untreated diabetic (DM), low-dose fasudil-treated (L-Fas), high-dose fasudil-treated (H-Fas) and captopril-treated (Cap) groups. Streptozotocin was injected to establish the diabetes model. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and inflammatory factors such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), were analyzed. Hematoxylin and eosin (HE) and Masson's trichrome staining were used for histological observations. The expression of transforming growth factor-β (TGF-β1), metalloproteinase-9 (MMP-9)/tissue inhibitor of metalloproteinase-1 (TIMP-1), collagen type Iα (Coll α1), nuclear factor-kappa B (NF-κB) and ROCK-1 were measured to investigate the mechanisms involved in fibrosis. RESULTS The DM group exhibited hepatic fibrosis with remarkable liver damage and inflammation reaction by the activation of the NF-κB pathway. Treatment with fasudil or captopril suppressed not only the inflammation reaction but also the accumulation of the extracellular matrix due to the downregulation of TGF-β1 and MMP-9/TIMP-1, which induces the amelioration of the liver fibrosis with diabetes. Furthermore, fasudil significantly attenuated the activation of ROCK-1 and NF-κB in the livers of diabetic rats. CONCLUSIONS These results suggest that fasudil exert anti-inflammation actions and markedly decrease the accumulation of extracellular matrix. Fasudil is a good candidate agent for treating hepatic fibrosis in diabetes.
Collapse
Affiliation(s)
- Y Xie
- Department of Pharmacology, Hebei Medical University, Shijiazhuang, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Yuan Y, Wang LY, Mei J, Cheng Y, Wang W, Chu L, Tang J, Li N, Li HH, He WX, Yang LL, Chen J, Bai YS, Wu Y, Liang JB, Sun SY, Zhang X, Yang XD. [Protective effect of excretory-secretory protein from adult Trichinella spiralis on ovalbumin-induced allergic rhinitis in mice]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2019; 31:504-509. [PMID: 31713379 DOI: 10.16250/j.32.1374.2019069] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To investigate the protective effect of excretory-secretory protein (AES) from adult Trichinella spiralis on ovalbumin (OVA)-induced allergic rhinitis in mice. METHODS Eighteen female BALB/c mice were randomly divided into three groups, including the blank control group (Group A), OVA-induced rhinitis group (Group B) and AES treatment group (Group C). Mice in Group A were given PBS. Mice in Group B were intraperitoneally injected with antigen adjuvant suspension for systemic sensitization, once every other day for seven times; then, local excitation was intranasally induced with 5% OVA solution once a day for seven times to establish a mouse model of allergic rhinitis. In addition to induction of allergic rhinitis, mice in Group C were given 25 μg AES at baseline sensitization and local excitation. Following the final challenge, mice were observed for 30 min in each group, and the behavioral score was evaluated. The serum levels of IFN-γ, IL-4, IL-5, IL-10 and TGF-β were determined using an enzyme-linked immunosorbent assay in mice, and the pathological changes of mouse nasal mucosa were observed under a microscope. RESULTS There was a significant difference in the mouse behavioral scores among the three groups (F = 110.12, P < 0.01). The mouse behavioral score was significantly higher in Group B than in Group A (7.17 ± 0.75 vs. 1.33 ± 0.52, P < 0.01), and more remarkable pathological damages of mouse nasal mucosa were seen in Group B than in Group A, while the mouse behavioral score was significantly decreased in Group C than in Group B (P < 0.01), and the pathological damages of mouse nasal mucosa remarkably alleviated in Group C relative to Group B. There was a significant difference in serum IFN-γ level among the three groups (F = 7.50, P < 0.01) and the serum IFN-γ level in Group B was significantly lower than in group A and C (both P < 0.05). There were significant differences in serum IL-4 (F = 470.81, P < 0.01) and IL-5 levels (F =68.20, P < 0.01) among the three groups, and significantly greater serum IL-4 and IL-5 levels were detected in Group B than in Group A (P < 0.01), while significantly lower serum IL-4 and IL-5 levels were detected in Group C than in Group B (P < 0.01). There were significant differences in serum IL-10 (F = 174.91, P < 0.01) and TGF-β levels (F = 9.39, P < 0.01) among the three groups, and significantly greater serum IL-10 and TGF-β levels were seen in Group C than in Group B (both P < 0.05). CONCLUSIONS T. spiralis AES has a remarkable protective activity against OVA-induced allergic rhinitis in mice.
Collapse
Affiliation(s)
- Y Yuan
- Department of Basic Medical Sciences, Bengbu Medical College, Bengbu 233000, China.,Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - L Y Wang
- Department of Basic Medical Sciences, Bengbu Medical College, Bengbu 233000, China.,Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - J Mei
- The Second Affiliated Hospital of Bengbu Medical College, China
| | - Y Cheng
- Department of Pathogenic Infection and Immunity, Wuxi Medical School, Jiangnan University, China
| | - W Wang
- The First Affiliated Hospital of Bengbu Medical College, China
| | - L Chu
- The Second Affiliated Hospital of Bengbu Medical College, China
| | - J Tang
- Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - N Li
- Department of Basic Medical Sciences, Bengbu Medical College, Bengbu 233000, China
| | - H H Li
- Department of Basic Medical Sciences, Bengbu Medical College, Bengbu 233000, China
| | - W X He
- Department of Basic Medical Sciences, Bengbu Medical College, Bengbu 233000, China
| | - L L Yang
- Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - J Chen
- Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - Y S Bai
- Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - Y Wu
- Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - J B Liang
- Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - S Y Sun
- Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - X Zhang
- Anhui Provincial Key Laboratory of Infection and Immunity, China
| | - X D Yang
- Department of Basic Medical Sciences, Bengbu Medical College, Bengbu 233000, China.,Anhui Provincial Key Laboratory of Infection and Immunity, China
| |
Collapse
|
29
|
Zhang JP, Liao DQ, Li L, Chu L. Reduced c-Fos expression in orexin neurons of the lateral hypothalamic area and the locus coeruleus following injection of spinosin into mice. Folia Morphol (Warsz) 2019; 79:429-437. [PMID: 31724150 DOI: 10.5603/fm.a2019.0118] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 10/09/2019] [Accepted: 10/12/2019] [Indexed: 11/25/2022]
Abstract
BACKGROUND Spinosin, a major component of Samen Ziziphi spinosae, has been shown to modulate sedation and hypnosis; however, the underlying neuronal mechanisms of its stimulatory effects remain unclear. MATERIALS AND METHODS In the present study, we injected spinosin (15 mg/kg) or saline into mice, which were killed after 90 min. We isolated the brains, which were immunohistochemically stained for c-Fos as a biomarker for neuronal activation and assessed the expression profile of c-Fos in various sleep-arousal brain areas. RESULTS Our findings revealed that there were no statistically significant differences in the expression of c-Fos in the nucleus accumbens and ventrolateral preoptic area, the vertical limb of the diagonal band nucleus, horizontal limb of the diagonal band nucleus, ventral tuberomammillary nucleus, ventral tegmental area, and dorsal raphe nucleus relative to saline between saline and spinosin-treated mice. Unlike saline, spinosin markedly decreased c-Fos expression in the lateral hypothalamic area (LHA) as well as the locus coeruleus (LC). Compared to the saline injection, the application of spinosin also resulted in a marked decrease in c-Fos expression in the LHA orexin neurons. CONCLUSIONS These findings suggest that spinosin administration results in a restricted pattern of c-Fos expression within the LHA orexin neurons and the LC, suggesting that this particular neuronal inactivation contributes to sedation and hypnosis.
Collapse
Affiliation(s)
- J P Zhang
- Department of Anatomy, Histology and Embryology, Basic Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
| | - D Q Liao
- Clinical Practice Teaching Centre, Zhejiang Chinese Medical University, Hangzhou, China
| | - L Li
- Department of Physiology, Basic Medical College, Zhejiang Chinese Medical University, Hangzhou, China
| | - L Chu
- Department of Physiology, Basic Medical College, Zhejiang Chinese Medical University, Hangzhou, China
| |
Collapse
|
30
|
Chu L, Liang F, Zhang J, Deng J, Chen Y, Liu Q, Ai D, Zhu Z, Zhao K. A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Andic F, Miller A, Brown G, Chu L, Lin J, Liu T, Sertdemir Y, Torres M. Instruments for Determining Clinically Relevant Fatigue in Breast Cancer Patients during Radiotherapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Chu L, Fwa TF. Evaluation of surface infiltration performance of permeable pavements. J Environ Manage 2019; 238:136-143. [PMID: 30849598 DOI: 10.1016/j.jenvman.2019.02.119] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 02/03/2019] [Accepted: 02/25/2019] [Indexed: 06/09/2023]
Abstract
Many different test methods are used in practice to evaluate the surface infiltration performance of permeable pavements. This has led to inconsistency in reporting of test results. This study recognizes the differences in nature between a soil infiltration study and the surface infiltration evaluation of permeable pavements, and identifies the main issues associated with the current practice of surface infiltration testing. It proposes that hydraulic conductivity be adopted as the flow property for measurement and reporting instead of the commonly used infiltration rate. The advantages of measuring hydraulic conductivity are elaborated from both theoretical and practical implementation points of view. The theoretical merits of providing a consistent and integrated treatment of surface infiltration performance of a permeable pavement during the design, construction and maintenance phases are presented. The practical benefits are addressed from the following aspects: consistency between laboratory and field testing, uniformity in reporting of test measurements, rationality in construction quality control and acceptance checking, effectiveness in surface infiltration performance monitoring, and enhanced ability in implementing effective maintenance management. It is emphasized that the techniques and methods needed for measuring hydraulic conductivity of permeable pavement materials, for laboratory testing as well as on-site field testing, are already readily available and have been used by researchers and some practitioners for surface infiltration testing. Two falling-head test methods are recommended: one applies Darcy's law and determines hydraulic conductivity in the conventional way; another measures the time history of falling head and calculates hydraulic conductivity using a modified Darcy equation. It is also highlighted that the measurement of hydraulic conductivity offers a convenient platform for assessing the durability of a permeable pavement against clogging.
Collapse
Affiliation(s)
- L Chu
- School of Highway, Chang'an University, South Erhuan Middle Section, Xi'an, 710064, China
| | - T F Fwa
- Chang'an University, China; National University of Singapore, Singapore.
| |
Collapse
|
33
|
Standaert B, Dort T, Linden J, Madan A, Bart S, Chu L, Hayney MS, Kosinski M, Kroll R, Malak J, Meier G, Segall N, Schuind A. Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03 A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study. Health Qual Life Outcomes 2019; 17:80. [PMID: 31060567 PMCID: PMC6501410 DOI: 10.1186/s12955-019-1147-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Accepted: 04/25/2019] [Indexed: 01/25/2023] Open
Abstract
BACKGROUND This study aims to describe the short-term reactogenicity of the AS03-adjuvanted H5N1 vaccine expressed through adverse events (AEs) and quality-adjusted life-day (QALD) scores. The AEs are likely to be short-term and therefore the quality of life (QoL) questionnaire, SF-36v2, was administered daily to record changes over seven days. A more sensitive application of this instrument should allow for a better understanding of short-term tolerability of adjuvanted vaccines. METHODS Participants (N = 50) received a 2-dose vaccination schedule. Solicited (collected daily: days 0 to 7 [post dose 1] and 21 to 28 [post dose 2]) and unsolicited (collected weekly until day 21) AEs were collected via diary cards. The QoL questionnaires were completed daily (days 0-6) and weekly (days 0, 6, 21, 27) after dose one. Questionnaire data were transformed into SF-6D scores to report QALDs. It was hypothesized post-hoc that the QALD and daily AEs scores should correlate if discrete QoL-changes were captured. RESULTS Pain (92%) and muscle ache (66%) were the most commonly reported solicited local and general AEs respectively, neither increased in intensity nor in frequency after dose 2. No safety concerns were identified during the study. A correlation between the daily AEs and QALD scores existed (correlation coefficient, - 0.97 (p < 0.001)). The impact of the AEs scores on the QALD was marginal (- 0.02 max for one day). CONCLUSION Similarly with other H5N1 studies, no safety concern was identified throughout the study. Some time-limited variations in QALD-scores were reported. Our results imply that daily administration of the SF-36v2 captures changes in QALD-scores. TRIAL REGISTRATION ClinicalTrials.gov . NCT01788228. Registered 11 February 2013.
Collapse
Affiliation(s)
- B Standaert
- GSK, 20 Avenue Fleming, 1300, Wavre, Belgium.
| | - T Dort
- Keyrus Management SA c/o GSK, Wavre, Belgium.,Present address: Biogen International GmbH, Baar, Switzerland
| | | | | | - S Bart
- Optimal Research LLC, Rockville, MD, USA
| | - L Chu
- Benchmark Research, Austin, TX, USA
| | - M S Hayney
- School of Pharmacy, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA
| | | | - R Kroll
- Seattle Women's: Health, Research, Gynecology, University of Washington, Seattle, WA, USA
| | - J Malak
- University of Wisconsin-Madison, Madison, WI, USA
| | - G Meier
- Eisai, Woodcliff Lake, NJ, USA
| | - N Segall
- Clinical Research Atlanta, Stockbridge, GA, USA
| | | |
Collapse
|
34
|
Shan S, Li HF, Yang XY, Guo S, Guo Y, Chu L, Xu MJ, Xin DM. Higher lncRNA CASC15 expression predicts poor prognosis and associates with tumor growth in cervical cancer. Eur Rev Med Pharmacol Sci 2019; 23:507-512. [PMID: 30720157 DOI: 10.26355/eurrev_201901_16862] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To investigate the role of long non-coding RNA Cancer Susceptibility Candidate 15 (CASC15) in cervical cancer and its potential molecular mechanism. PATIENTS AND METHODS The CASC15 expression was measured in cervical cancer tissues and cell lines by using quantitative Real-time polymerase chain reaction (qRT-PCR) analysis. Cell counting kit-8 (CCK8), flow cytometry analysis and transwell cell invasion assays were employed to detect the capacities of cell proliferation and cell invasion. Furthermore, Western blot analysis was applied to detected the E-cadherin and N-cadherin expression in EMT pathway. RESULTS We demonstrated that lncRNA CASC15 expression was higher in cervical cancer tissues compared to adjacent normal tissues. Higher lncRNA CASC15 expression associated with lymph node metastasis and FIGO stage. Moreover, our results showed that higher lncRNA CASC15 expression predicted poor prognosis of cervical cancer. Functional assays showed that knockdown of lncRNA CASC15 suppressed cell proliferation and cell cycle progression in cervical cancer. Moreover, we also found that knockdown of lncRNA CASC15 inhibited cell invasion ability and Epithelial-Mesenchymal Transition (EMT) signaling pathway by upregulating E-cadherin and downregulating N-cadherin expression in cervical cancer. CONCLUSIONS These results indicated that lncRNA CASC15 expression may be a prognostic biomarker and contributed to cell proliferation and invasion in cervical cancer.
Collapse
Affiliation(s)
- S Shan
- Department of Gynecology and Obstetrics, Affiliated Tongji Hospital, Tongji University, Shanghai, China.
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Li X, Guo D, Chu L, Huang Y, Zhang F, Li W, Chen J. Potential Diagnostic Value Of Combining Inflammatory Cell Ratios With Carcinoembryonic Antigen For Colorectal Cancer. Cancer Manag Res 2019; 11:9631-9640. [PMID: 32009818 PMCID: PMC6861168 DOI: 10.2147/cmar.s222756] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 10/21/2019] [Indexed: 02/05/2023] Open
Abstract
PURPOSE To evaluate the diagnostic value of combining the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) or lymphocyte-monocyte ratio (LMR) with carcinoembryonic antigen (CEA) in patients with colorectal cancer (CRC). PATIENTS AND METHODS The diagnostic performance of inflammatory makers and CEA was evaluated in cohort 1 (664 patients with CRC, 336 patients with colorectal polyps and 664 healthy controls) and validated in cohort 2 (87 patients with CRC and 87 healthy controls) by using receiver operating characteristic curve analysis. RESULTS In cohort 1, the NLR, PLR and CEA levels were significantly higher, while the LMR was markedly lower in patients with CRC than in healthy controls. The PLR and LMR were significantly associated with invasion depth and lymph node metastasis. Moreover, significant differences in the PLR and LMR were observed between patients with stage I/II CRC and healthy or polyp controls and those with stage III/IV CRC. Using the NLR, PLR or LMR with CEA resulted in a significantly larger area under the curve (AUC) than any of them used alone. Combining the PLR and LMR with CEA exhibited the best diagnostic value for CRC (AUC=0.892). The AUCs of this combination were 0.864 and 0.783 for distinguishing stage I/II CRC from healthy and polyp controls, respectively. When we used the same cut-off values to assess the diagnostic ability of these markers in cohort 2, similar results were observed, and the PLR, LMR and CEA combination also showed the highest accuracy (AUC=0.936). CONCLUSION Combining inflammatory cell ratios with CEA could improve the diagnostic efficacy for CRC patients. The combination of the PLR and LMR with CEA might be a valuable indicator in the early detection and monitoring of CRC patients.
Collapse
Affiliation(s)
- Xinxin Li
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, People’s Republic of China
| | - Dongming Guo
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, People’s Republic of China
| | - Lingyu Chu
- Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, People’s Republic of China
| | - Yiteng Huang
- Department of Health Care Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, People’s Republic of China
| | - Feiran Zhang
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, People’s Republic of China
| | - Wei Li
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, People’s Republic of China
| | - Juntian Chen
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, People’s Republic of China
- Correspondence: Juntian Chen Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, 57 Changping Road, Shantou515041, Guangdong Province, People’s Republic of ChinaTel/Fax +86 754 8890 5256 Email
| |
Collapse
|
36
|
Huang X, Hong C, Peng Y, Yang S, Huang L, Liu C, Chen L, Chu L, Xu L, Xu Y. The Diagnostic Value of Serum IGFBP7 in Patients with Esophageal Squamous Cell Carcinoma. J Cancer 2019; 10:2687-2693. [PMID: 31258777 PMCID: PMC6584926 DOI: 10.7150/jca.32393] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Accepted: 05/01/2019] [Indexed: 02/05/2023] Open
Abstract
Esophageal squamous cell cancer (ESCC) is one of the leading malignant cancer in the world and especially in China with high incidence and mortality. The exploration of novel serum biomarkers is required for early detection of ESCC. We investigated the diagnostic value of serum insulin like growth factor binding protein 7 (IGFBP7) in ESCC, evaluating its potential to improve the diagnosis of ESCC. The serum samples of 106 patients with ESCC and 107 normal controls were tested by enzyme-linked immunosorbent assay (ELISA). The levels of IGFBP7 in ESCC group were significantly higher than that in normal controls, compared by the Mann-Whitney U test (P<0.0001). Using receiver operating characteristic (ROC) curve, the diagnostic value of serum IGFBP7 was demonstrated. Versus normal group, the area under the ROC curve (AUC) of all ESCC was 0.794 (95%CI: 0.735-0.853) and early-stage ESCC was 0.725 (95%CI: 0.633-0.817). With optimized cutoff value of 2.993 ng/mL, IGFBP7 showed certain diagnostic value with specificity of 90.7%, sensitivities of 40.6% and 32.4% in ESCC and early-stage ESCC, respectively. Considering the correlation between clinical data and IGFBP7, no significant association was found (all P>0.05). Thus, we supposed that serum IGFBP7 might be a potential biomarker in the diagnosis of ESCC.
Collapse
Affiliation(s)
- Xinyi Huang
- Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou 515041
| | - Chaoqun Hong
- Department of Oncological Laboratory Research, the Cancer Hospital of Shantou University Medical College, Shantou 515041
| | - Yuhui Peng
- Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou 515041
- The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041
- Guangdong Esophageal Cancer Research Institute, Shantou University Medical College, Shantou 515041
| | - Shihan Yang
- Department of Dermatology and Venereology, Shantou Central Hospital, Shantou 515041
| | - Lisheng Huang
- Department of Radiation Oncology, the Cancer Hospital of Shantou University Medical College, Shantou 515041
| | - Cantong Liu
- Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou 515041
| | - Liuyi Chen
- Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou 515041
| | - Lingyu Chu
- The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041
| | - Liyan Xu
- The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041
- Guangdong Esophageal Cancer Research Institute, Shantou University Medical College, Shantou 515041
- Institute of Oncologic Pathology, Shantou University Medical College, Shantou 515041, China
- ✉ Corresponding authors: Yiwei Xu, Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou 515041, PR China; ; telephone number: +86-159-8970-1200. Correspondence may also be addressed to Liyan Xu, E-mail:
| | - Yiwei Xu
- Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou 515041
- The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou 515041
- Guangdong Esophageal Cancer Research Institute, Shantou University Medical College, Shantou 515041
- ✉ Corresponding authors: Yiwei Xu, Department of Clinical Laboratory Medicine, the Cancer Hospital of Shantou University Medical College, Shantou 515041, PR China; ; telephone number: +86-159-8970-1200. Correspondence may also be addressed to Liyan Xu, E-mail:
| |
Collapse
|
37
|
Chu L, Fung HH. AGE DIFFERENCES IN THE EMOTIONAL AND MOTIVATIONAL EXPERIENCE OF LONELINESS: A TIME-SAMPLING STUDY. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- L Chu
- The Chinese University of Hong Kong, Shatin, Hong Kong
| | - H H Fung
- The Chinese University of Hong Kong, Hong Kong
| |
Collapse
|
38
|
Zhang F, Hu S, Wang H, Chu L, Kwok T, Fung H. HOW STRUCTURAL AND COGNITIVE SOCIAL CAPITAL INFLUENCE COGNITIVE FUNCTIONING: COMPARING YOUNG-OLDS AND OLD-OLDS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Zhang
- The Chinese University of Hong Kong
| | - S Hu
- The National Cheng Kung University
| | - H Wang
- Beijing National Day School
| | - L Chu
- The Chinese University of Hong Kong
| | - T Kwok
- The Chinese University of Hong Kong
| | - H Fung
- The Chinese University of Hong Kong
| |
Collapse
|
39
|
Chu L, Kelly K, Gandara D, Lara P, Borowsky A, Meyers F, Mcpherson J, Erlich R, Almog N, Schrock A, Ali S, Ross J, Miller V, Heilmann A, Riess J. P3.13-26 Outcomes of Patients with Metastatic Lung Cancer Presented in a Multidisciplinary Molecular Tumor Board. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1867] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Huang Q, Xu Z, Li R, Wang YG, Shu YQ, Yang Y, Hu XQ, Chu L, Qiu W. [Analysis of clinical characteristics and prognosis of neuromyelitis optic spectrum disease complicated with malignant tumor]. Zhonghua Yi Xue Za Zhi 2018; 98:2496-2500. [PMID: 30139002 DOI: 10.3760/cma.j.issn.0376-2491.2018.31.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the clinical features of patients involved with both malignant tumors and neuromyelitis optica spectrum disorders (NMOSD). Methods: The clinical data of 473 patients with NMOSD admitted into the Third Affiliated Hospital of Sun Yat-sen University and the Department of Neurology, Affiliated Hospital of Guizhou Medical University from June 2012 to March 2017 were retrospectively analyzed. Eleven NMOSD patients complicated with malignant tumors were screened out (3 with breast cancer, 2 with cervical cancer, 2 with rectal cancer, 2 with leukemia, 1 with nasopharyngeal carcinoma, 1 with thyroid cancer). Fifty patients without NMOSD were included as controls. Results: Most of the NMOSD patients were complicated by low-moderately differentiated squamous cell carcinoma/adenocarcinoma, mainly seen in breast, reproductive system, digestive system and hematological system. In terms of sex ratio and autoantibodies, the NMOSD patients with and without malignant tumors showed no significant difference. However, comparing to the patients without malignant tumor, the ones with malignant tumor showed a tendency of lower rate of initial brain symptoms and relapse rate, while with older onset age, higher initial EDSS score, protein content in cerebrospinal fluid (CSF), higher rates of initial symptom resulted from the focus of posterior region of the medulla and of significant image focus. Of the 8 NMOSD patients who diagnosed as malignant tumors in our hospital, 2 with breast cancer and 1 with cervical cancer had a good prognosis (follow-up EDSS score <3). All the 3 patients received aggressive surgery and chemotherapy treatment. However, the other 5 patients had poor prognosis (follow-up EDSS score ≥3 points). All the 11 patients received anti-tumor therapy, 4 patients had first NMOSD attack after anti-tumor treatment and no relapse. Only one case from the remaining 7 patients had relapse; Among the 9 patients received immunosuppressive therapy, 7 patients had no relapse, and 8 cases maintained stable; while, among all the 9 patients received immunosuppressive agents and anti-tumor therapy, only one case had relapse. Conclusions: There are some differences in the clinical features between the NMOSD patients with malignant tumors and the NMOSD patients without malignant tumors. Immunosuppressive therapy can improve the prognosis of patients with NMOSD and tumor, without increasing the risk of malignant tumor. The pathological type, staging and antitumor therapy may influence the prognosis of NMOSD. NMOSD patients with malignant tumor could be treated with anti-tumor and immunosuppressive agents if needed.
Collapse
Affiliation(s)
- Q Huang
- Department of Neurology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Chu L. The 9 th Annual Biosimilar Asia 2018 (May 16-17, 2018 - Shanghai, China). Drugs Today (Barc) 2018; 54:445-449. [PMID: 30090881 DOI: 10.1358/dot.2018.54.7.2866120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The 9th Annual Biosimilar Asia, an event hosted by ICB Asia, was held at the Hilton Shanghai Hongqiao from May 16 to 17. It was held simultaneously with Biomanufacturing Asia, and Cell Line Development and Engineering Asia. These three events formed Biopharma Development and Production (BDP) 2018. The BDP 2018 event had more than 60 sessions, over 70 speakers and more than 300 companies from around the world.
Collapse
Affiliation(s)
- L Chu
- Clarivate Analytics, Beijing, China.
| |
Collapse
|
42
|
Duan H, Chen X, Li Z, Pang Y, Jing W, Liu P, Wu T, Cai C, Shi J, Qin Z, Yin H, Qiu C, Li C, Xia Y, Chen W, Ye Z, Li Z, Chen G, Wang S, Liu Y, Chu L, Zhu M, Xu T, Wang Q, Wang J, Du Y, Wang J, Chu N, Xu S. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect 2018; 25:190-195. [PMID: 30036672 DOI: 10.1016/j.cmi.2018.07.012] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 07/05/2018] [Accepted: 07/10/2018] [Indexed: 01/23/2023]
Abstract
OBJECTIVES We carried out a randomized multicentre study in China to investigate whether the clofazimine would improve the efficacy of the standardized regimen in patients with multidrug-resistant tuberculosis (MDR-TB). METHODS Patients with MDR-TB managed in 17 TB specialist hospitals in China between September 2009 and September 2011 were randomly assigned to the treatment groups at enrolment. In the intervention group, 100 mg clofazimine per day was added to the standardized regimen. The primary outcome was the proportion of patients with successful outcomes. RESULTS From the 156 patients that were screened, 74 were assigned to the control group and 66 to the clofazimine group. Of the 66 cases analysed for clinical outcome in the clofazimine group, 36 patients were cured, and seven completed treatment, yielding a favourable outcome rate of 65.1%. The proportion of patients with favourable outcomes receiving the control regimen was 47.3% (35/74), which was significantly lower than that in the clofazimine group (p 0.034, relative risk 0.661, 95% CI 0.243-0.949). CONCLUSIONS The addition of clofazimine to the standard regimen improved the treatment of MDR-TB.
Collapse
Affiliation(s)
- H Duan
- Department of Tuberculosis, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumour Research Institute, Beijing, China
| | - X Chen
- Department of Tuberculosis, Pulmonary Hospital of Fuzhou of Fujian Province, Fuzhou, China
| | - Z Li
- Department of Tuberculosis, Hebei Chest Hospital, Shijiazhuang, China
| | - Y Pang
- National Clinical Laboratory on Tuberculosis, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumour Research Institute, Beijing, China
| | - W Jing
- Department of Tuberculosis, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumour Research Institute, Beijing, China
| | - P Liu
- Department of Respiratory Medicine, The People's Hospital of Changshou Distirct, Chongqing, China
| | - T Wu
- Department of Respiratory Medicine, The Second Affiliated Hospital of Chengdu, Chongqing Medical University, China
| | - C Cai
- Department of Tuberculosis, Guiyang Pulmonary Hospital, Guiyang, China
| | - J Shi
- Department of Tuberculosis, The Sixth People's Hospital of Nantong City Jiangsu Province, Nantong, China
| | - Z Qin
- Department of Tuberculosis, The Sixth People's Hospital of Nantong City Jiangsu Province, Nantong, China
| | - H Yin
- Department of Tuberculosis, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai, China
| | - C Qiu
- Department of Drug-resistant Tuberculosis, Jiamusi Tuberculosis Control Hospital, Jiamusi, China
| | - C Li
- The Third Ward of Pulmonary Hospital, Changsha Central Hospital, Changsha, China
| | - Y Xia
- The Third Ward of Pulmonary Hospital, Changsha Central Hospital, Changsha, China
| | - W Chen
- Department of Tuberculosis, Shenyang Chest Hospital, Liaoning Province Shenyang, China
| | - Z Ye
- Department of Pulmonary, The First Affiliated Hospital of Xiamen University, Xiamen, China
| | - Z Li
- Department of Tuberculosis, Liaoyang Tuberculosis Hospital of Liaoning Province, Liaoyang, China
| | - G Chen
- Department of Tuberculosis, Chongqing Pulmonary Hospital, Chongqing, China
| | - S Wang
- Department of Thoracic Surgery, Chest Hospital of Xinjiang Uyghur Autonomous Region of the PRC, Wulumuqi, China
| | - Y Liu
- Department of Chest, Qingdao Chest Hospital, Qingdao, China
| | - L Chu
- Department of Tuberculosis, The Seventh People's Hospital of Mudanjiang, Mudanjiang, China
| | - M Zhu
- Tuberculosis Treatment Centre, Hangzhou Red Cross Hospital, Hangzhou, China
| | - T Xu
- Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, China
| | - Q Wang
- Department of Tuberculosis, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumour Research Institute, Beijing, China
| | - J Wang
- Department of Tuberculosis, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumour Research Institute, Beijing, China
| | - Y Du
- Department of Tuberculosis, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumour Research Institute, Beijing, China
| | - J Wang
- Department of Tuberculosis, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumour Research Institute, Beijing, China
| | - N Chu
- Department of Tuberculosis, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumour Research Institute, Beijing, China.
| | - S Xu
- Department of Thoracic Surgery, Beijing Chest Hospital Affiliated to Capital Medical University, Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, China.
| |
Collapse
|
43
|
Chu L, Corvino F, Yi J, Zivkovic M, Wong W. P3.01-086 Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Chu L, Zhang M, Ran Y. Further progress for therapeutic solutions in psoriasis. Br J Dermatol 2017; 177:896-897. [PMID: 29052872 DOI: 10.1111/bjd.15845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- L Chu
- Department of Dermatology, West China Hospital, Sichuan University, China, 610041
| | - M Zhang
- Department of Dermatology, West China Hospital, Sichuan University, China, 610041
| | - Y Ran
- Department of Dermatology, West China Hospital, Sichuan University, China, 610041
| |
Collapse
|
45
|
Kaufman P, Hurvitz S, O'Shaughnessy J, Mason G, Yardley D, Brufsky A, Rugo H, Cobleigh M, Swain S, Tripathy D, Chu L, Antao V, Yoo B, Jahanzeb M. Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
46
|
Jahanzeb M, Tripathy D, Hurvitz S, O'Shaughnessy J, Mason G, Yardley D, Brufsky A, Rugo H, Cobleigh M, Swain S, Chu L, Antao V, Yoo B, Kaufman P. First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Chu L, Xu X, Ran Y. Primary cutaneous nocardiosis caused by Nocardia brasiliensis
following a wasp sting. Clin Exp Dermatol 2017; 42:416-419. [PMID: 28397286 DOI: 10.1111/ced.13086] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2016] [Indexed: 02/05/2023]
Affiliation(s)
- L. Chu
- Department of Dermatology; West China Hospital; Sichuan University No. 37 of Guo Xue Xiang; Chengdu Sichuan China
| | - X. Xu
- Department of Dermatology; West China Hospital; Sichuan University No. 37 of Guo Xue Xiang; Chengdu Sichuan China
| | - Y. Ran
- Department of Dermatology; West China Hospital; Sichuan University No. 37 of Guo Xue Xiang; Chengdu Sichuan China
| |
Collapse
|
48
|
Ding RJ, Gao LM, Chu L, Xie WL, Wang XR, Tang Q, Wang HL, Hu DY. [Efficacy and safety of tertiary hospital guided and community-driven family self-help cardiac rehabilitation model]. Zhonghua Xin Xue Guan Bing Za Zhi 2017; 45:209-216. [PMID: 28316177 DOI: 10.3760/cma.j.issn.0253-3758.2017.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Objective: To explore the efficacy and safety of tertiary hospital guided and community-driven family self-help cardiac rehabilitation model. Methods: This study was a prospective randomized controlled study, 80 patients from Beijing Electrical Power Hospital and Beijing Jingmei Group General Hospital with acute coronary syndrome were included from June to December 2015 and divided into 2 groups. Patients in rehabilitation group (n=52) received tertiary hospital(Peiking University Peoples' Hospital) guided and community-driven family self-help cardiac rehabilitation for 3 months, and patients in control group (n=28) received routine secondary treatment for 3 months. Following parameters including 6 minutes walk distance, score of life quality (evaluated by Short Form-12), score of anxiety (evaluated by Generalized Anxiety Disorder-7), score of depression (evaluated by Perceived Health Questionnaire-9), self-management competency (evaluated by questionnaire) were collected at baseline and after treatment for 3 months. Results: Compared with control group, 6 minutes walk distance was longer in rehabilitation group((60.2±6.8) meters vs. (24.9±10.5)meters, P<0.01). The difference values between after and before intervention of life quality scores((0.14±3.90)scores vs.(-7.44±5.85)scores, P>0.05), anxiety scores((-0.16±2.12 ) scores vs.(0.70±1.13)scores, P>0.05) and depression scores((-1.17±2.79) scores vs.(0.60±0.36)scores, P>0.05) were similar between the 2 groups. The amplification of patients with regular exercise (50.26% vs. 0, P<0.05), limit sugary foods usually and always (53.22% vs. 3.98%, P<0.05), eat 200-400 g fruits usually and always (78.61 % vs. 0, P<0.05), eat 300-500 g vegetables usually and always (9.74% vs. 0, P<0.05), and answering very confident to questions such as let the physicians know about your diseases (40.17% vs. 5.00%, P<0.05), know how to take medicines (44.52% vs. 5.00%, P<0.05), know how much exercise was right for yourself (26.43% vs.0, P<0.05) were significantly higher in rehabilitation group than in control group. There were no cardiac rehabilitation training related cardiovascular events. Conclusion: Tertiary hospital guided and community-driven family self-help cardiac rehabilitation model is an effective and safe management model of cardiovascular disease in chronic phase, and it is necessary to further expand the study population to verify the efficacy of this model.
Collapse
Affiliation(s)
- R J Ding
- Department of Cardiology, Peking University People's Hospital, Beijing 100044, China
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Jahanzeb M, Tripathy D, Rugo H, Swain S, Kaufman PA, Mayer M, Hurvitz S, O'Shaughnessy J, Mason G, Yardley DA, Brufsky A, Chu L, Antao V, Beattie M, Yoo B, Cobleigh M. Abstract P5-08-27: Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction In 2010, the cutoff for HR positivity in breast cancer was established as ≥1% of cells staining HR+, previously having varied from 1% to 10%. The impact of this change on treatment patterns and outcomes is poorly understood. SystHERs is a prospective, observational cohort registry of patients (pts) with HER2+ metastatic breast cancer (MBC) that commenced enrollment in 2012. To our knowledge, SystHERs is the largest registry to collect and analyze data for the HER2+ subgroup. We report baseline characteristics, treatment patterns, and early outcomes by %HR+ (1–9% vs 10–100%).
Methods SystHERs enrolled pts aged ≥18 years and within 6 months of HER2+ MBC diagnosis. For pts with locally-determined HR+ disease, defined as HR+ in primary or metastatic tissue, %HR+ is the highest percentage of ER+ or PR+ tissue in early breast cancer or MBC. The percentage of ER+ or PR+ cells was not reported for pts considered HR– by the investigator. Median overall survival (OS; Kaplan–Meier) and hazard ratios (Cox regression) were estimated.
Results As of Feb 1, 2016, data were available for 872 eligible pts with known HR status, of whom 608 (70%) had HR+ disease. Of the 608 pts, 53 (9%) had 1–9%HR+ and 496 (82%) had 10–100%HR+; %HR+ was not reported for 59 pts. Baseline characteristics were similar between %HR+ subgroups (Table 1).
As shown in Table 2, the 1–9%HR+ subgroup was less likely to receive first-line hormonal therapy (26%) than the 10–100%HR+ subgroup (56%). 87% and 79% of pts received chemotherapy, respectively.
Median time from MBC diagnosis was 16.5 months (range, 0.4–49.4 months). Median OS was not reached at the data cutoff. The number of deaths was 13 (25%) in the 1–9%HR+ subgroup, and 68 (14%) in the 10–100%HR+ subgroup (log-rank P=0.025). The OS hazard ratio (0.514, 95% CI 0.283–0.931) favored the 10–100%HR+ subgroup. OS did not differ significantly between pts with 1–9%HR+ vs HR– disease (log-rank P=0.582, hazard ratio 1.185, 95% CI 0.647–2.169).
Table 1. Baseline characteristics 1-9%HR+ (n=53)10-100%HR+ (n=496)HR– (n=264)Age at MBC diagnosis, median yrs (range)54 (30–86)57 (21–86)55 (28–88)Race, % White838372Black151320Premenopausal, %282522ECOG performance status, % 04654441463942≥2878MBC diagnosis type, % De novo404958Recurrent605142Visceral, %*686275*Non-hepatic abdominal, ascites, CNS, liver, lung, or pleural effusion sites of metastasis
Table 2. First-line treatment 1-9%HR+ (n=53)10-100%HR+ (n=496)HR– (n=264)HER2-targeted therapy, %969391Chemotherapy, %877989Hormonal therapy, %26564
Conclusions These preliminary observational data suggest potential differences in treatment patterns and survival outcomes in low vs moderate/high HR+ expressers, with the former being less likely to receive hormonal therapy (26% vs 56%). Furthermore, low HR positivity was associated with poorer OS and was similar to OS observed in pts with HR– disease.
Citation Format: Jahanzeb M, Tripathy D, Rugo H, Swain S, Kaufman PA, Mayer M, Hurvitz S, O'Shaughnessy J, Mason G, Yardley DA, Brufsky A, Chu L, Antao V, Beattie M, Yoo B, Cobleigh M. Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-27.
Collapse
Affiliation(s)
- M Jahanzeb
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - D Tripathy
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - H Rugo
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - S Swain
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - PA Kaufman
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - M Mayer
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - S Hurvitz
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - J O'Shaughnessy
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - G Mason
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - DA Yardley
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - A Brufsky
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - L Chu
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - V Antao
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - M Beattie
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - B Yoo
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| | - M Cobleigh
- University of Miami Sylvester Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Washington Cancer Institute, MedStar Washington Hospital Center; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center; AdvancedBC.org; UCLA Jonsson Comprehensive Cancer Center and Translational Research in Oncology; Baylor Charles A. Sammons Cancer Center, Texas Oncology, US Oncology; Inflammatory Breast Cancer Research Foundation; Sarah Cannon Research Institute and Tennessee Oncology, PLLC; University of Pittsburgh Cancer Institute; Genentech, Inc.; Rush University Medical Center
| |
Collapse
|
50
|
Chu L, Yoo B, Carrigan G, Lai C, Beattie M, Reyes C. Abstract P5-08-24: How do real-world treatment patterns compare to guideline recommendations for first-line metastatic breast cancer patients in US community clinics? Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-08-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Treatment (txt) guidelines are based on trial data from a small minority of patients (pts). Linked electronic health records (EHRs) are a novel approach to examine txt patterns and outcomes in larger and more generalizable populations. Given the increasing importance of real world data and real world outcomes, we utilized linked EHRs from a network of US community clinics to examine how real world txt patterns compare to metastatic breast cancer (mBC) txt guideline recommendations.
Methods:
The Flatiron database provides real world clinical data collected from EHRs used by US cancer care providers. The Flatiron network comprises ~15% of US cancer pts and is geographically and demographically diverse.
Using EHR from Jan 2016 mBC database, we evaluated first-line (1L) txt patterns in mBC by molecular subtype. Pts were selected if they received mBC txt within 60 days of mBC diagnosis between 01Jan2011-31Dec2015, had ≥2 visits within the Flatiron Network on or after 01Jan2013, and were ≥18 years (yrs). Analyses were conducted to describe pt and clinical characteristics and 1L txt by HER2 and/or hormone receptor (HR) status.
Results:
Among 2509 mBC pts identified, 58.9% were HR+/HER2-, 17.7% HER2+, 11.6% HR-/HER2- (triple negative, TNBC), 7.4% HER2 equivocal, and 4.3% 'not done/unknown HER2 status'. Txt patterns in the latter two groups were not analyzed. Selected pt and disease characteristics by subtype are shown in Table 1. Median follow-up since mBC diagnosis was 1.1 yrs (range 0-5 yrs). The 1L mBC txts by subtype are shown in Table 2. Pts with HR+/HER2- subtype were treated primarily with hormonal therapy (68%) and/or chemotherapy (chemo) (35%). Among HER2+ pts, the 1L mBC txt patterns include trastuzumab+pertuzumab with chemo (31%), trastuzumab with chemo (22%), trastuzumab with hormonal therapy (9%), ado-trastuzumab (4%), lapatinib with chemo (3%), and lapatinib with hormonal therapy (1%). For TNBC, the majority received chemo (95%), such as paclitaxel (21%), nab-paclitaxel (13%) and docetaxel (12%).
Conclusion:
This study advances our current understanding of real world 1L patterns of care by molecular subtype among mBC pts and how these compare to guideline recommendations. While the majority of pts are receiving therapy per guidelines, up to 22% of HER2+ of pts are not receiving targeted therapy in 1L mBC
Table 1. Patient and disease characteristics by subtypeN (%)HR+/HER2- (N=1479)HER2+ (N=445)TNBC (N=291)Age at mBC diagnosis (yrs), median (range)66 (24-85)60 (27-85)60 (33-85)Sex Female1459 (99)441 (99)289 (99)Race White995 (67)274 (62)168 (58)Black112 (8)44 (10)42 (14)Asian19 (1)14 (3)5 (2)Other179 (12)50 (11)36 (12)Missing173 (12)63 (14)40 (14)MBC type De novo418 (28)172 (39)94 (32)Recurrent881 (60)225 (51)178 (61)Unknown180 (12)48 (11)19 (7)HR Status Positive1479 (100)300 (67)--Negative--145 (33)291 (100)
Table 2. 1L mBC treatments by subtypeN (%)HR+/HER2- (N=1479)HER2+ (N=445)TNBC (N=291)Any Targeted Therapy*77 (5)346 (78)12 (4)Any Chemotherapy521 (35)283 (64)276 (95)Any Hormonal Therapy1010 (68)115 (26)16 (6)*Targeted therapy includes trastuzumab, pertuzumab, ado-trastuzumab emtansine, lapatinib and bevacizumab
Citation Format: Chu L, Yoo B, Carrigan G, Lai C, Beattie M, Reyes C. How do real-world treatment patterns compare to guideline recommendations for first-line metastatic breast cancer patients in US community clinics? [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-24.
Collapse
Affiliation(s)
- L Chu
- Genentech, Inc, South San Francisco, CA
| | - B Yoo
- Genentech, Inc, South San Francisco, CA
| | | | - C Lai
- Genentech, Inc, South San Francisco, CA
| | - M Beattie
- Genentech, Inc, South San Francisco, CA
| | - C Reyes
- Genentech, Inc, South San Francisco, CA
| |
Collapse
|